Zepbound vs Wegovy: Which Is Right for a Mother?

The short version

Zepbound (tirzepatide) and Wegovy (semaglutide) are the two FDA-approved brand-name injections for weight loss. They're often talked about as interchangeable, but a head-to-head trial now separates them: over 72 weeks, Zepbound produced meaningfully more weight loss than Wegovy, and was declared superior on that measure¹. For a mother, though, the decision isn't only the bigger number. Side effects, cost, breastfeeding and pregnancy timing, and a birth-control interaction that applies to Zepbound but not Wegovy all belong in the same conversation.

One naming note first, because it causes confusion: Zepbound and Wegovy are the brands approved for weight loss. The same two molecules are sold as Mounjaro (tirzepatide) and Ozempic (semaglutide) for type 2 diabetes. Same drugs, different brand and indication.

The head-to-head data

Most comparisons used to lean on separate trials. Now there's a direct one. SURMOUNT-5 randomized 751 adults with obesity to Zepbound or Wegovy for 72 weeks at their maximum tolerated doses. Mean weight change was −20.2% with tirzepatide versus −13.7% with semaglutide, and tirzepatide was superior for both weight and waist-circumference reduction¹. That result lines up with each drug's own pivotal obesity trial — semaglutide produced about 15% average weight loss in STEP 1², and tirzepatide about 20% at the top dose in SURMOUNT-1³ — so the direction is consistent across the evidence, not a one-study fluke.

The honest caveat: "more on average" is a statement about groups, not about you. Plenty of women lose a great deal on semaglutide, tolerate it better, or pay less for it. The trial tells you where the averages point, not where a single person will land.

Side effects: same family, mostly during dose increases

Both drugs are built on GLP-1 signaling (Zepbound adds a second target, GIP), so the side-effect profile rhymes. Gastrointestinal effects — nausea, diarrhea, constipation, vomiting — are the most common with both, most are mild to moderate, and they cluster during the dose-escalation phase rather than at a stable maintenance dose¹. Neither is the "gentle" option in any reliable way; tolerance is individual, and a good program titrates slowly and adjusts if a molecule doesn't sit well.

Staying there: the maintenance question

Weight loss that reverses the moment you stop isn't the goal, and this is where a mother's-eye view helps. Both drugs are studied as ongoing treatments. When semaglutide was stopped and switched to placebo, much of the lost weight came back⁴. Continuing tirzepatide, by contrast, maintained the reduction where stopping did not⁵. If you might pause treatment for a pregnancy, "what happens when I stop, and how do I restart" is a more useful question than "which number is bigger."

Cost and access

Zepbound is frequently priced higher than Wegovy, and a formal cost-effectiveness analysis built on the SURMOUNT-5 results examined that value trade-off directly in the US setting⁶. Both manufacturers run savings programs, both come as fixed-dose pens, and real-world availability of each has swung with shortages. For most mothers the practical driver is what insurance covers and what the out-of-pocket number actually is — worth pricing before you fix on a molecule.

The mother-specific differences a brand name skips

Two facts matter here that a straight efficacy comparison leaves out:

• Birth control. The Zepbound label carries an explicit warning that oral hormonal contraceptives may become less effective, and advises switching to a non-oral method or adding a barrier method around starting the drug and around each dose increase⁷. The Wegovy labeling does not carry that specific warning⁸. If you rely on the pill, that is not a footnote — it's a real difference between the two.
• Breastfeeding and pregnancy timing. Both are off the table during pregnancy and while breastfeeding, and both linger roughly a week per dose, so the washout math is broadly similar. If you're nursing or planning to conceive, the timing plan matters more than the molecule — our guide to GLP-1s and breastfeeding walks through how clinicians think about it.

How to actually choose

The averages favor Zepbound, but averages aren't individuals. Tolerance, cost, what your insurance covers, whether you use oral contraception, and your pregnancy plans all feed a real decision — and a good program can switch molecules if the first isn't the right fit. That flexibility, under genuine clinical oversight, is exactly what our Metabolic-Fit Score methodology rewards; clinician-led options such as CoreAge Rx sit near the top of our semaglutide vs tirzepatide board for that reason. If you're curious whether a smaller dose is a reasonable starting point, see our guide to microdosing GLP-1s for mothers. Bring your history and plans to a clinician and decide together rather than picking from a brand name. This article is educational only and not medical advice.